# Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients

> **NCT04040816** · PHASE2 · COMPLETED · sponsor: **Shanton Pharma Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Gout
- Hyperuricemia

## Interventions

- **DRUG:** SAP-001

## Key facts

- **NCT ID:** NCT04040816
- **Lead sponsor:** Shanton Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-01
- **Primary completion:** 2020-08-01
- **Final completion:** 2020-08-30
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04040816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04040816, "Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04040816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*